News

The experiments in space aim to tailor the physico-chemical formulation process in order to reach elevated drug efficiency for COVID-19 treatment. Moreover, the potential enhancement of the remdesivir-SBECD ratio in the drug (i.e., lowering SBECD intake) will contribute to its lower risk application for coronavirus infected patients with decreased renal functions.

The companies will use research facilities of Japan Manned Space Systems Corporation (JP) and Space Applications Services (BE) and will launch their remdesivir samples to the European Space Agency’s Columbus module on the International Space Station (ISS) by the SpaceX Dragon cargo resupply mission (CRS-21) in early December 2020.

Read more: cyclodextrinnews.com/2020/11/11/first-experiments-in-space-for-covid-19-drug-research/

BACK TO NEWS